Related Experiment Videos
Treatment of infantile spasms with high-dosage vitamin B6
J Pietz1, C Benninger, H Schäfer
1Department of Child Neurology, University of Heidelberg, Federal Republic of Germany.
Insights
High-dose vitamin B6 (pyridoxine-HCl) shows promise for treating infantile spasms. Five children responded positively, becoming seizure-free within weeks with minimal side effects, warranting further clinical trials.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Infantile spasms are a severe epilepsy syndrome in infants.
- Current treatments like ACTH/corticosteroids and valproate have significant side effects.
- High-dose vitamin B6 is explored as a potential alternative therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of high-dose vitamin B6 as an initial treatment for infantile spasms.
- To identify potential responders to vitamin B6 therapy.
Main Methods:
- Seventeen children with recently diagnosed infantile spasms received high-dose vitamin B6 (300 mg/kg/day orally).
- Children were classified as symptomatic (with brain lesions) or cryptogenic.
- Response was defined by seizure freedom and absence of infantile spasms relapse.
Main Results:
- Five out of 17 children (29.4%) responded to high-dose vitamin B6.
- Responders became seizure-free within 2-4 weeks.
- No serious adverse reactions were observed; gastrointestinal symptoms were reversible.
Conclusions:
- High-dose vitamin B6 demonstrates potential efficacy and a favorable safety profile for infantile spasms.
- Further controlled clinical trials are justified to confirm its therapeutic value.
- Vitamin B6 may offer a safer alternative to conventional treatments for infantile spasms.
Abstract:
High-dose vitamin B6 (pyridoxine-HCl, 300 mg/kg/day orally) was introduced as the initial treatment of recently manifested infantile spasms in 17 children (13 symptomatic cases with identified brain lesion and 4 cryptogenic cases). 5 of 17 children (2 cryptogenic, 2 with severe pre/perinatal brain damage and one with Sturge-Weber syndrome) were classified as responders to high-dose vitamin B6. In all 5 cases the response to vitamin B6 occurred within the first 2 weeks of treatment and within 4 weeks all patients were free of seizures. Two patients developed other seizures (partial seizures, etiologically unclear blinking attacks), but no relapse of infantile spasms was observed among the five responders to vitamin B6. No serious adverse reactions were noted. Side effects were mainly gastrointestinal symptoms, which were reversible after reduction of the dosage. Considering the life-threatening side effects of treatment with ACTH/corticosteroids or valproate, a controlled clinical trial with high-dose vitamin B6 would appear justified to either prove or disprove efficacy.